EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 5 (Mai 2023) Med Sci (Paris), 39 5 (2023) 445-451 Références
Open Access
Numéro
Med Sci (Paris)
Volume 39, Numéro 5, Mai 2023
Page(s) 445 - 451
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023066
Publié en ligne 23 mai 2023
  1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020 : An overview. Int J Cancer 2021; Apr 5. doi : 10.1002/ijc.33588. [PubMed] [Google Scholar]
  2. Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer : Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol Mech Dis 2021; 16 : 223–49. [CrossRef] [PubMed] [Google Scholar]
  3. Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer 2021; 20 : 28. [CrossRef] [PubMed] [Google Scholar]
  4. Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of immunotherapy : A mechanistic perspective. J Exp Med 2021; 218 : e20192179. [CrossRef] [PubMed] [Google Scholar]
  5. Toi Y Sugawara S, Sugisaka J, et al. Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2019 ; 5 : 376–383. [CrossRef] [PubMed] [Google Scholar]
  6. Dougan M, Wang Y, Rubio-Tapia A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis : Expert Review. Gastroenterology 2021; 160 : 1384–93. [CrossRef] [PubMed] [Google Scholar]
  7. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017 ; 28 : 368–376. [CrossRef] [PubMed] [Google Scholar]
  8. Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6 : 38. [CrossRef] [PubMed] [Google Scholar]
  9. Dow ER, Yung M, Tsui E. Immune Checkpoint Inhibitor-associated Uveitis : Review of Treatments and Outcomes. Ocul Immunol Inflamm 2021; 29 : 203–11. [CrossRef] [PubMed] [Google Scholar]
  10. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016 ; 375 : 1749–1755. [Google Scholar]
  11. Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T cell repertoire. Cancer Res 2017 ; 77 : 1322–1330. [PubMed] [Google Scholar]
  12. Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 2018 ; 33 : 570–580. [CrossRef] [PubMed] [Google Scholar]
  13. Laparra A, Champiat S, Michot J-M, et al. [Management of adverse events associated with cancer immunotherapy]. Rev Prat 2021; 71 : 400–7. [PubMed] [Google Scholar]
  14. La Rochefoucauld J de, Noël N, Lambotte O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients : a patient-centred approach. Intern Emerg Med 2020; 15 : 587–98. [CrossRef] [PubMed] [Google Scholar]
  15. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : ASCO guideline update. J Clin Oncol 2021; 39 : 4073–126. [CrossRef] [PubMed] [Google Scholar]
  16. Malviya N, Tattersall IW, Leventhal J, et al. Cutaneous immune-related adverse events to checkpoint inhibitors. Clin Dermatol 2020; 38 : 660–78. [CrossRef] [PubMed] [Google Scholar]
  17. Tang L, Wang J, Lin N, et al. Immune Checkpoint Inhibitor-associated colitis : From mechanism to management. Front Immunol 2021; 12 : 800879. [CrossRef] [PubMed] [Google Scholar]
  18. Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep 2017 ; 19 : 3. [CrossRef] [PubMed] [Google Scholar]
  19. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, Version 1.2019. J Natl Compr Canc Netw 2019 ; 17 : 255–289. [CrossRef] [PubMed] [Google Scholar]
  20. Martin ED, Michot J-M, Rosmorduc O, et al. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Report 2020; 2. [Google Scholar]
  21. Chuzi S, Tavora F, Cruz M, et al. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 2017 ; 9 : 207–213. [CrossRef] [Google Scholar]
  22. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis : a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014 ; 99 : 4078–4085. [CrossRef] [PubMed] [Google Scholar]
  23. Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis : a retrospective cohort study. Clin Cancer Res 2015 ; 21 : 749–755. [CrossRef] [PubMed] [Google Scholar]
  24. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors : Review of the literature. Eur J Cancer 2017 ; 73 : 1–8. [CrossRef] [PubMed] [Google Scholar]
  25. Liu X, Wang Z, Zhao C, et al. Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thorac Cancer 2020; 11 : 810–8. [CrossRef] [PubMed] [Google Scholar]
  26. Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2021; 80 : 36–48. [CrossRef] [PubMed] [Google Scholar]
  27. Shah M, Tayar JH, Abdel-Wahab N, et al. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 2019 ; 48 : 736–740. [CrossRef] [PubMed] [Google Scholar]
  28. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011 ; 365 : 1747–1748. [CrossRef] [PubMed] [Google Scholar]
  29. Perazella MA, Shirali AC. Immune checkpoint inhibitor nephrotoxicity : what do we know and what should we do? Kidney Int 2020; 97 : 62–74. [CrossRef] [PubMed] [Google Scholar]
  30. Jain V, Bahia J, Mohebtash M, et al. Cardiovascular complications associated with novel cancer immunotherapies. Curr Treat Options Cardiovasc Med 2017 ; 19 : 36. [CrossRef] [PubMed] [Google Scholar]
  31. van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease : A cohort study. Ann Intern Med 2021; 174 : 641–8. [CrossRef] [PubMed] [Google Scholar]
  32. Sroussi M, Fluckiger A, Zitvogel L. Un bactériophage du microbiote intestinal induit une réponse anti-tumorale par un mécanisme de réactivité croisée. Med Sci (Paris) 2021; 37 : 970–2. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.